Broad-Spectrum Antiviral Strategies and Nucleoside Analogues
Open Access
- 13 April 2021
- Vol. 13 (4), 667
- https://doi.org/10.3390/v13040667
Abstract
The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health threats due to the absence of available treatments. Vaccines represent a key answer to control these viruses. However, in the case of a public health emergency, vaccine development, safety, and partial efficacy concerns may hinder their prompt deployment. Thus, developing broad-spectrum antiviral molecules for a fast response is essential to face an outbreak crisis as well as for bioweapon countermeasures. So far, broad-spectrum antivirals include two main categories: the family of drugs targeting the host-cell machinery essential for virus infection and replication, and the family of drugs directly targeting viruses. Among the molecules directly targeting viruses, nucleoside analogues form an essential class of broad-spectrum antiviral drugs. In this review, we will discuss the interest for broad-spectrum antiviral strategies and their limitations, with an emphasis on virus-targeted, broad-spectrum, antiviral nucleoside analogues and their mechanisms of action.Keywords
This publication has 96 references indexed in Scilit:
- Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir)Molecular Pharmacology, 2013
- The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus PolymerasePLOS ONE, 2013
- T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In VitroJournal of Virology, 2013
- Risk in Vaccine Research and Development QuantifiedPLOS ONE, 2013
- RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complexProceedings of the National Academy of Sciences of the United States of America, 2012
- Characterizing the Epidemiology of the 2009 Influenza A/H1N1 Pandemic in MexicoPLoS Medicine, 2011
- Viral Mutation RatesJournal of Virology, 2010
- The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479)Bioorganic & Medicinal Chemistry Letters, 2009
- Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In VivoJournal of Virology, 2009
- Lassa FeverThe New England Journal of Medicine, 1986